Arc Group Securities Acquisition I receives Nasdaq notice on warrant listing
Arc Group Securities Acquisition I receives Nasdaq notice on warrant listing
ARC Group Securities Acquisition I (NASDAQ:FJDIU) announced it received a written notice from the Listing Qualifications Department of The Nasdaq Stock Market on Monday regarding its warrants. The notice stated that the aggregate market value of the company’s outstanding warrants has fallen below the $1 million minimum required under Nasdaq Listing Rule 5452(b)(C) for continued listing on the Nasdaq Global Market.
According to the company’s statement, the notice serves as a notification of deficiency and does not currently affect the listing or trading of ARC Group Securities Acquisition I’s warrants on Nasdaq. The notice applies only to the company’s warrants and does not impact the listing or trading of its other securities.
The company now has 45 calendar days, until December 4, 2026, to submit a plan to Nasdaq outlining how it intends to regain compliance with the listing requirement. If Nasdaq accepts the plan, the company may be granted an extension of up to 180 calendar days from the date of the notice, or until April 18, 2027, to meet the compliance criteria. If Nasdaq does not accept the plan, the company may appeal the decision to a hearings panel.
ARC Group Securities Acquisition I stated it intends to submit a compliance plan within the required period. The company also noted that if it does not regain compliance by the end of any granted extension, its warrants could become subject to delisting, with the right to appeal any such determination.
This information is based on a statement included in the company’s recent SEC filing.
Related Articles
- Insider Trading News
T3 Defense says it has regained compliance with Nasdaq equity requirement
- Insider Trading News
Innventure receives Nasdaq notice for minimum bid price non-compliance
- Insider Trading News
Laser Photonics receives Nasdaq notice for minimum bid price non-compliance
- Insider Trading News
Akebia Therapeutics receives Nasdaq notice for minimum bid price deficiency
- Crypto News
SEC puts tokenization risks on its fiscal 2027 examination list